{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:35:43Z","timestamp":1792758943761,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.anai.2024.09.021","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T16:03:07Z","timestamp":1728489787000},"page":"19-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The role of biologics in inducing remission in asthma"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-4696","authenticated-orcid":false,"given":"William W.","family":"Busse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10118","key":"10.1016\/j.anai.2024.09.021_bib0001","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.anai.2024.09.021_bib0002","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMcp2304871","article-title":"Asthma in adults","volume":"389","author":"Mosnaim","year":"2023","journal-title":"N Engl J Med"},{"issue":"10379","key":"10.1016\/j.anai.2024.09.021_bib0003","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.anai.2024.09.021_bib0004","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and difficult-to-treat asthma in adults","volume":"377","author":"Israel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2024.09.021_bib0005","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Updated May 2024. Accessed August 15, 2024. Available at: www.ginasthma.org."},{"issue":"8","key":"10.1016\/j.anai.2024.09.021_bib0006","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2024.09.021_bib0007","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.09.021_bib0008","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.anai.2020.04.031","article-title":"How to compare the efficacy of biologic agents in asthma","volume":"125","author":"Viswanathan","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9743","key":"10.1016\/j.anai.2024.09.021_bib0009","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0140-6736(10)61380-3","article-title":"Role of viral respiratory infections in asthma and asthma exacerbations","volume":"376","author":"Busse","year":"2010","journal-title":"Lancet"},{"issue":"9347","key":"10.1016\/j.anai.2024.09.021_bib0010","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.anai.2024.09.021_bib0011","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2024.09.021_bib0012","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.anai.2024.09.021_bib0013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.anai.2024.09.021_bib0014","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.anai.2024.09.021_bib0015","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of Benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.anai.2024.09.021_bib0016","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2024.09.021_bib0017","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.anai.2024.09.021_bib0018","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"10335","key":"10.1016\/j.anai.2024.09.021_bib0019","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(22)00331-2","article-title":"Disease-modifying anti-asthmatic drugs","volume":"399","author":"Lommatzsch","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.anai.2024.09.021_bib0020","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2024.09.021_bib0021","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaip.2020.10.035","article-title":"The relationship of asthma biologics to remission for asthma","volume":"9","author":"Menzies-Gow","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2024.09.021_bib0022","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.09.021_bib0023","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2024.09.021_bib0024","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaci.2006.01.011","article-title":"Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists","volume":"117","author":"Schatz","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.09.021_bib0025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2024.09.021_bib0026","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"issue":"5","key":"10.1016\/j.anai.2024.09.021_bib0027","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jaip.2015.05.005","article-title":"Progression of irreversible airflow limitation in asthma: correlation with severe exacerbations","volume":"3","author":"Matsunaga","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2024.09.021_bib0028","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, & Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.09.021_bib0029","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.anai.2024.09.021_bib0030","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2024.09.021_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.09.021_bib0032","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2024.09.021_bib0033","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.anai.2024.09.021_bib0034","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5r: results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.anai.2024.09.021_bib0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2024.09.021_bib0036","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.anai.2024.09.021_bib0037","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/jcm13010291","article-title":"Clinical remission in patients affected by severe eosinophilic asthma on dupilumab therapy: a long-term real-life study","volume":"13","author":"Quarato","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.anai.2024.09.021_bib0038","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1164\/rccm.202305-0808OC","article-title":"Association between T2-related comorbidities and effectiveness of biologics in severe asthma","volume":"209","author":"Wechsler","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2024.09.021_bib0039","doi-asserted-by":"crossref","unstructured":"Pelaia C, Crimi C, Benfante A, Caiaffa MF, Campisi R, Candia C, et al. Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis [e-pub ahead of print]. Respirology. https:\/\/doi.org\/10.1111\/resp.14767, accessed August 15, 2024.","DOI":"10.1111\/resp.14767"},{"issue":"6","key":"10.1016\/j.anai.2024.09.021_bib0040","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01844-2023","article-title":"Clinical remission with biologic therapies in severe asthma: a matter of definition","volume":"62","author":"Beasley","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2024.09.021_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107528","article-title":"Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy","volume":"222","author":"Breslavsky","year":"2024","journal-title":"Respir Med"},{"issue":"10423","key":"10.1016\/j.anai.2024.09.021_bib0042","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624015576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624015576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:27:27Z","timestamp":1735658847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624015576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1081120624015576"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.09.021","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of biologics in inducing remission in asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}